; and (C) considers pain, pain control, or pain management in assessing whether a disease or condition is a serious or life-threatening disease or condition; and (2) the methods by which sponsors may evaluate acute and chronic pain, endpoints for non-addictive medical products intended to treat pain, the manner in which endpoints and evaluations of efficacy will be applied across and within review divisions, taking into consideration the etiology of the underlying disease, and the manner in which sponsors may use surrogate endpoints, intermediate endpoints, and real world evidence. (c) Medical product defined In this section, the term medical product means a drug (as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(g)(1) )), biological product (as defined in section 351(i) of the Public Health Service Act ( 42 U.S.C. 262(i) )), or device (as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321(h) )). 3002. Surveillance and Testing of Opioids to Prevent Fentanyl Deaths (a) Public health laboratories to detect fentanyl Part F of title III of the Public Health Service Act ( 42 U.S.C. 262 et seq.) is amended— (1) in the heading of part F, by striking and clinical laboratories and inserting , clinical laboratories, and public health laboratories ; and (2) by adding at the end the following new subpart: 4 Public Health Laboratories 355. Public health laboratories to detect fentanyl (a) In general The Secretary shall establish a program to award grants to Federal, State, and local agencies to support the establishment or operation of public health laboratories to detect fentanyl, its analogues, and other synthetic opioids, as described in subsection (b). (b) Standards The Secretary, in consultation with the Director of the National Institute of Standards and Technology, shall— (1) develop standards for safely and effectively handling and testing fentanyl, its analogues, and other synthetic opioids